Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

The Egyptian Journal of Bronchology

Table 1 Patient characteristics

		n (%)
Age (years)	<75	70 (53.8%)
Age (years)	≥75	60 (46.2%)
Sex	Male	48 (36.9%)
Sex	Female	82 (63.1%)
Histology	Adenocarcinoma	125 (96.2%)
Histology	Others	5 (3.8%)
EGFR mutation	Exon 19 del	56 (43.1%)
	Exon 21 L858R	62 (47.7%)
	Uncommon mutation	12 (9.2%)
PS	0–1	93 (71.5%)
PS	≥2	37 (28.5%)
LDH (U/L)	<200	58 (44.6%)
LDH (U/L)	≥200	72 (55.4%)
Tumor PD-L1 TPS	≥1%	36 (27.7%)
	<1%	24 (18.5%)
	Unknown	70 (53.8%)
History of surgery	Yes	22 (16.8%)
History of surgery	No	109 (83.2%)
Brain metastasis	Yes	37 (28.5%)
Brain metastasis	No	93 (71.5%)
First-line EGFR-TKI used	1st-generation TKIs	84 (64.6%)
	Afatinib	25 (19.2%)
	Osimertinib	21 (16.2%)
History of platinum-doublet therapy	Yes	36 (27.7%)
History of platinum-doublet therapy	No	94 (72.3%)
History of VEGF inhibitor therapy	Yes	5 (3.8%)
History of VEGF inhibitor therapy	No	125 (96.2%)
Sequential therapy with TKIs	Osimertinib	21 (16.2%)
	1st/2nd-generation TKIs	16 (12.3%)
	None	93 (71.5%)
History of ICI therapy	Yes	13 (10.0%)
History of ICI therapy	No	117 (90.0%)

EGFR epidermal growth factor receptor, ICI immune checkpoint inhibitor, LDH serum lactate dehydrogenase, PD-L1 programmed death ligand 1, PS performance status, TKI tyrosine kinase inhibitor, TPS tumor proportion score, VEGF vascular endothelial growth factor